Satsuma Pharma at 2-yr high as migraine product shows positive tolerability

Satsuma Pharmaceuticals

20/09/2022 18:21

** Shares of Satsuma Pharmaceuticals  STSA.O  up 10.8% at
$7.70 after positive results from ongoing Phase 3 safety trial
for co's migraine product - hitting their highest since
September 2020
    ** STS101 nasal powder for migraines demonstrated a
favorable safety and tolerability profile, consistent with
clinical experience to date - STSA
    ** Co to announce trial results in Q4 of 2022, and move to
submit a new drug application (NDA) with the U.S. Food and Drug
Administration in Q1 of 2023
    ** Stock set for best day since Aug. 5 
    ** So far this year, STSA was up nearly 51%, as of last
close

    

 (Reporting by Savyata Mishra in Bengaluru)
 ((Savyata.mishra@thomsonreuters.com))